IBRX Quote, Financials, Valuation and Earnings

Hims & Hers Health, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of 2.63%. ImmunityBio, Inc.'s return on equity of -- beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

ImmunityBio, Inc. has a consensus price target of $10.20, signalling upside risk potential of 345.42%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $44.36 which suggests that it could grow by 13.17%. Given that ImmunityBio, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe ImmunityBio, Inc. is more attractive than Hims & Hers Health, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.414, suggesting its more volatile than the S&P 500 by 141.424%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. ImmunityBio, Inc.'s net income of -$67.3M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 72.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 23.73x versus 4.40x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -135.28%. ImmunityBio, Inc.'s return on equity of -- beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

ImmunityBio, Inc. has a consensus price target of $10.20, signalling upside risk potential of 345.42%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that ImmunityBio, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Iovance Biotherapeutics, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. ImmunityBio, Inc.'s net income of -$67.3M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 23.73x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of 38.89%. ImmunityBio, Inc.'s return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

ImmunityBio, Inc. has a consensus price target of $10.20, signalling upside risk potential of 345.42%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that ImmunityBio, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe ImmunityBio, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. ImmunityBio, Inc.'s net income of -$67.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 23.73x versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Summit Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of --. ImmunityBio, Inc.'s return on equity of -- beat Summit Therapeutics, Inc.'s return on equity of -283.98%.

ImmunityBio, Inc. has a consensus price target of $10.20, signalling upside risk potential of 345.42%. On the other hand Summit Therapeutics, Inc. has an analysts' consensus of $32.06 which suggests that it could grow by 75.08%. Given that ImmunityBio, Inc. has higher upside potential than Summit Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Summit Therapeutics, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Summit Therapeutics, Inc. has a beta of -1.523, suggesting its less volatile than the S&P 500 by 252.256%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Summit Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Summit Therapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Summit Therapeutics, Inc. quarterly revenues of --. ImmunityBio, Inc.'s net income of -$67.3M is higher than Summit Therapeutics, Inc.'s net income of -$231.8M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Summit Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 23.73x versus 21,812.02x for Summit Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.